We believe that the latter is an interesting asset, not only because we demonstrated the capacity of 18F12 to discriminate AD patients from non-AD individuals based on CSF ELISA, but also because this mAb allows insight in the structural differences between Tau splicing isoforms and the roles played by the amino-terminal inserts. This evidence concerns the gene MAPT and Alzheimer disease.